Key facts
- This page summarizes Stella Xu's Form 4 filing for NextCure, Inc. (NXTC).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 28 Jun 2021, 18:16.
Stella Xu - 24 Jun 2021 Form 4 Insider Report for NextCure, Inc. (NXTC)
- Reporting relationship
- Director
- Issuer ticker
- NXTC
- Reported as of
- 24 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2021, 18:16:25 UTC
- Next SEC filing
- 29 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven P. Cobourn, as attorney-in fact for Stella Xu
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stella Xu filed Form 4 for NextCure, Inc. (NXTC) on 28 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NXTC
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +14,250
- Change %
- Price
- $0.000000
- Shares after
- 14,250
- Date
- 24 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,250
- Exercise price
- $8.21
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders.